- North American Vaccine: $10 million invested, grew to $140 million, acquired by Baxter International (BAX)in 1999
- Whitman Education: $6 million invested, grew to $175 million, acquired by Career Education Corporation (CECO) in 2003 in a merger agreement.
- IVAX: $100 million invested (including open market purchases), grew to $1.5 billion, acquired by Teva Pharmaceuticals in 2006 for $7.4 billion. Funds that were invested from the 1987 IPO and held all the way until the 2006 acquisition achieved a return of 6,742%.
-Continucare: $16.8 million invested, grew to $170 million, acquired by Metropolitan Health Networks in 2011 for $416 million.
- Dreams Inc.: $2 million invested, grew to $15 million, acquired by Fanatics Inc. in 2012 for $183 million.
Dr. Phillip Frost, CEO of Opko Health:
A self-made billionaire with a proven track-record, Dr. Phillip Frost has expressed a great deal of confidence in Opko Health with massive insider buying. He has been buying shares of Opko Health in heavy volumes on a regular basis for the past two years. He has a net worth of $3.3 billion, and his investment trust holds a position in Opko that is worth approximately $1.5 billion. Dr. Frost has achieved great returns on his investments through various companies, many of which ended in eventual acquisitions:
- Key Pharmaceuticals: $5 million invested, grew to $180 million, acquired by Schering-Plough in 1986 for $600 million
OPKO presentation at AUA an important milestone, says Ladenburg
Ladenburg views OPKO Health’s acceptance to present at the American Urological Association annual meeting as an important commercial milestone to help it build awareness for its 4Kscore test. They reiterates its Buy rating and $14.50 price target on OPKO.
Kevin DeGeeter, Ladenburg Thalmann (3/25/14) “OPKO Health Inc. disclosed plans to launch 4Kscore in the U.S. by March 31. . .we continue to view the expected release in August of topline data from two phase 3 studies of Rayaldy for treatment of secondary hyperparathyroidism in stage 3 or 4 chronic kidney disease patients with vitamin D insufficiency as an important catalyst for the company’s shares. . .we reiterate our Buy rating and $14.50 price target.”
Stephen M. Zappala, MD FACS of Andover Urology. “The 4KscoreTM test offers new information on the probability of having a Gleason Score ≥ 7 cancer prior to undergoing a prostate biopsy. This is important, because we know that besides the potential side effects of biopsy such as bleeding and infection, up to 80% of prostate biopsies will either be negative for prostate cancer or will indicate a low grade disease that may be better monitored than treated. The 4KscoreTM test will offer both the Urologist and patient new information for the shared decision-making discussion about whether or not to have a prostate biopsy.”
Dr Dipen J Parekh serves as Professor and Chairman in the Department of Urology at the University of Miami Miller School of Medicine and Director of Robotic surgery for the University of Miami Health System. He is the holder of the Victor A Politano Endowed Chair in Urology. He was recently announced as the recipient of the Gold Cystoscope Award for 2013– the most prestigious award from the American Urology Association. He was the inaugural holder of the Doctors Hospital at Renaissance Distinguished University Chair in Urology in UT San Antonio. He serves as the Principal Investigator in a NCI sponsored RO1 grant for a multiinstitutional prospective randomized clinical trial comparing open and robotic cystectomy for bladder cancer. He recently completed a transformative prospective clinical trial of renal ischemia in patients undergoing partial nephrectomy. He has one of the largest experiences in the world in performing complex Robotic Urologic Oncologic surgeries for prostate, bladder and kidney cancers. He is recipient of the SWOG Young Investigator Award. He received his medical degree from Poona University followed by residencies in General Surgery and Urology from Mumbai University, India. He was awarded the Rotary International Ambassadorial Scholarship to pursue further training in the United States. He completed his Urology Residency at Vanderbilt University Medical Center followed by a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center. He completed an Executive Masters program in Healthcare Administration from Trinity University. He has published several scientific papers, abstracts and book chapters and served as an Assistant Editor for the Journal of Urology. He is an invited faculty and lecturer nationally and globally where he has launched several robotic urologic surgical programs.
The results demonstrated the 4Kscore Test is the most accurate, personalized predictor for risk of high-grade cancer. The data were presented by Dr. Daniel W. Lin, Professor and Chief of Urologic Oncology at the University of Washington, as a Late-Breaking abstract at the Plenary I Session on Sunday May 18, 2014 at the American Urological Association (AUA) annual meeting in Orlando, FL.
Hey Ice, I was reading the DEF 14A filed 4/25/2014, and I see that the "Frost Gamma Investments Trust "controls 171,235,404 shares of common stock, then the "Frost Group LLC" Controls 20,286,704 shares of the common stock. Then "Philip Frost MD " controls 174,079,355 shares. I don't see how they came up with Doc's number. Seems like Doc's number of shares beneficially owned should be 191,522,108
Frost already controls the company, between him and Jane I don't see how anyone would be able to stop them from taking it private IF he wanted to right now. He already does whatever whenever he wants to. No benefit to taking private, I do not see how that is a logical conclusion.
But it does emphasize what I have said all along, what's to stop him from buying the rest of the float whenever he wants? He could single handedly start a massive short squeeze, and now he has the green light from the FTC. ;}
Sentiment: Strong Buy